Mitsubishi Tanabe to Collaborate with Regeneron
Monday, October 5, 2015
Source: BioPharma Asia
Mitsubishi Tanabe Pharma Corporation and Regeneron Pharmaceuticals, Inc. have concluded a collaboration agreement as of September 29, 2015 for fasinumab (REGN475). Through this agreement, the Company has acquired exclusive development and commercialization rights for fasinumab in Japan, Korea and Asian countries, excluding China.
Fasinumab is an antibody that specifically binds to Nerve Growth Factor (NGF) which is believed to play a role in pain. In a Phase 2 clinical study regarding osteoarthritis in the U.S., Fasinumab demonstrated to promptly ameliorate moderate-to-severe pain. A Phase 2b/3 study for pain due to osteoarthritis was initiated in mid-2015 in the U.S. As a result of this agreement, the Company and Regeneron plan to move ahead with the development of fasinumab in Japan for indications of musculoskeletal pain, specifically osteoarthritis and chronic low back pain.